Publications 2020

Gruhn B, Brodt G, Wittig S, Ernst T, Ernst J. Molecular remission using three monoclonal antibodies followed by allogeneic bone marrow transplantation in an infant with refractory ALL. Ann Hematol. 2020 May;99(5):1133-1134. doi: 10.1007/s00277-020-03957-z. Epub 2020 Feb 18. PMID: 32067128

Tintelnot J, Goekkurt E, Binder M, Thuss-Patience P, Lorenzen S, Knorrenschild JR, Kretzschmar A, Ettrich T, Lindig U, Jacobasch L, Pink D, Al-Batran SE, Hinke A, Hegewisch-Becker S, Nilsson S, Bokemeyer C, Stein A. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217). BMC Cancer. 2020 Jun 1;20(1):503. doi: 10.1186/s12885-020-06958-3. PMID: 32487035; PMCID: PMC7268753

Sinn M, Liersch T, Riess H, Gellert K, Stübs P, Waldschmidt D, Lammert F, Maschmeyer G, Bechstein W, Bitzer M, Denzlinger C, Hofheinz R, Lindig U, Ghadimi M, Hinke A, Striefler JK, Pelzer U, Bischoff S, Bahra M, Oettle H. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results. Eur J Cancer. 2020 Oct;138:172-181. doi: 10.1016/j.ejca.2020.06.032. Epub 2020 Sep 2. PMID: 32890813

Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, Wörmann B, Cornely OA, Köhler P, Schalk E, von Lilienfeld-Toal M. Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Eur J Cancer. 2020 Nov;140:86-104. doi: 10.1016/j.ejca.2020.09.009. Epub 2020 Sep 21. PMID: 33068941; PMCID: PMC7505554

Schmitz C, Rekowski J, Müller SP, Farsijani N, Hertenstein B, Franzius C, von Verschuer U, La Rosée P, Freesmeyer M, Wilop S, Krohn T, Raghavachar A, Ganser A, Bengel FM, Prange-Krex G, Kroschinsky F, Kotzerke J, Giagounidis A, Dührsen U, Hüttmann A: Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy. Cancer Med. 2020 Nov;9(22):8386-8396. doi: 10.1002/cam4.3448. Epub 2020 Sep 14. PMID: 32926763; PMCID: PMC7666729

Hübner J, Keinki C, Zomorodbakhsch B. Onkologe 2020; https://doi.org/10.1007/s00761-019-00699-0

Hübner J, Steinhaußen J, Busch St, Liebers St, Laubscher U, Büntzel J, Keinki C. Onkologische Versorgung in strukturschwachen Regionen. Eine Aufgabe für Medizin, Politik und Gesellschaft; Forum 2020; 35:31–36

Hübner J, Keinki C, Zomorodbakhsch B. Bedrohliche Situationen durch komplementäre und alternative Medizin; Onkologe 2020; 26:169–177

Schneider N, Bäcker A, Brenk-Franz K, Keinki C, Hübner J, Brandt F, von der Winkel G, Hager L, Strauss B, Altmann U. Patient information, communication and competence empowerment in oncology (PIKKO) – evaluation of a supportive care intervention for overall oncological patients. Study protocol of a nonrandomized controlled trial; BMC Med Res Meth 2020:20:120

Keinki C, Zomorodbakhsch B, Hübner J. Antwort auf den Leserbrief von Helmut Kiene, Institut für angewandte Erkenntnistheorie und medizinische Methodologie; Onkologe 2020;26:566–568

Heller T, Kloos C , Mueller N, Roemelt J, Keinki C, Wolf G, Mueller UA, Huebner J. Complementary and alternative medicine is positively associated with religiousness/spirituality; J Complement Integr Med 2020; 20180023; doi.org/10.1515/jcim-2018-0023

Walter S, Keinki C, Hübner J. Therapieentscheidungen in der Onkologie Gratwanderung zwischen Ehrlichkeit und Hoffnung, Lebenszeit und Lebensqualität; HNO 2020; 68:492–497

Hübner J. Komplementäre Medizin in der Uroonkologie; Urologe 2020;59:695-699

Hübner J. Angst vor der Isolation; DÄB 2020;117(25):1266

Eisfeld H, Schmidt T, Muenstedt K, Guntinas-Lichius O, Micke O, Huebner J. Need for information and use of complementary and alternative medicine in oncologic patients: A cross-sectional study at a German tertiary care hospital; Trace Elements Electrolytes. 2020; 37: 45-54. doi: 10.5414/TEX01606.

Keinki C, Meyer H, Bozkurt G, Müller N, Römelt J, Müller UA, Hübner J. Salvation Expectations of Patients of Medicine, Complementary and Alternative Medicine and Religion; J Religion Health 2020, DOI 10.1007/s10943-020-01074-9

Männle H, Hübner J, Münstedt K. Beekeepers who tolerate bee stings are not protected against SARS-CoV-2 infections; Toxicon 2020;187:279–284

Zomorodbakhsch B, Keinki C, Seilacher E, Huebner J. Cancer Patients Numeracy and Preferences for Information Presentation—a Survey Among German Cancer Patients; J Cancer Educ 2020; 35:22–27

Büssing A, Hübner J, Walter S, Gießler W, Büntzel J. Tumor Patients´ Perceived Changes of Specific Attitudes, Perceptions, and Behaviors Due to the COVID-19 Pandemic and Its Relation to Reduced Wellbeing. Front. Psychiatry 2020;11:574314.doi: 10.3389/fpsyt.2020.574314

Scheerer B, Hübner J, Sanchez H, Buchholz D, Schmunz J, Traeger W, Selig L, Blumers A, Neubauer S, Heinemann V, Erickson N. Wissenschaftsbasierte Entwicklung von patientenorientierten Rezeptideen in der Onkologie (PRIO); Forum 2020, 35: 408–410

Steinau P, Walter S, Hübner J, Büntzel J. Subjektive Bedeutung des Riechverlusts nach Laryngektomie; HNO 2020; https://doi.org/10.1007/s00106-020-00956-4

Kowalski C, Hübner J. Patient-reported outcome measures – Reif für die Routine; Forum 2020;35:401-405

Hübner J, Poeck J, Keinki C, Salomo S. Digital communication for patient care – a new approach; Oncol Res Treat 2020;43(suppl 4):238

Hübner J. S3 guideline project: Complementary and alternative medicine; Oncol Res Treat 2020;43(suppl 4):15

Heß M, Schüle S, Lindig U, Ernst T, Diebolder H, Liebusch AK, Ma­thies V, Huebner J: Cancer and malnutrition – study of the nutri­tional status of patients on oncological wards versus their perso­nal-reflection. Ernahrungs Umschau 2020; 67(11): 206–12.

Büntzel J, Walter S, Hellmund H, Klein M, Hübner J, Vitek P, Büntzel J, Koscielny S, Sesterhenn AM, Büssing A. Auswirkgungen der Covid-19_Pandemie auf die Versorgung von HNO-Tumoren – die Patientenperspektive; Laryngo-Rhino-Otol. 2020 doi10.1055/a-1327-4234

Brioli A, vom Hofe F, Rucci P, Ernst T, Yomade O, Hilgendorf I, Scholl S, Sayer H, Mügge LO, Hochhaus A, von Lilienfeld-Toal M: Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients. Bone Marrow Transplant (2020). https://doi.org/10.1038/s41409-020-01170-0

Jayavelu AK, Schnöder TM, Perner F, Herzog C, Meiler A, Krishnamoorthy G, Huber N, Mohr J, Edelmann-Stephan B, Austin R, Brandt S, Palandri F, Schröder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hübner CA, Zeiser R, Rahmig S, Waskow C, Coldham I, Ernst T, Hochhaus A, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M & Heidel FH: Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature (2020). https://doi.org/10.1038/s41586-020-2968-3

Gresing LJ, Radon P, Friedrich RP, Zahn D, Raasch M, Mosig AS, Dutz S, Alexiou C, Wiekhorst F, Hochhaus A, Clement JH: Negatively charged magnetic nanoparticles pass the blood-placenta barrier under continuous flow conditions in a time-dependent manner. Journal of Magnetism and Magnetic Materials, Available online 10 November 2020, 167535, https://doi.org/10.1016/j.jmmm.2020.167535

Rummelt C, Gorantla SP, Meggendorfer M, Charlet A, Endres C, Döhner K, Heidel FH, Fischer T, Haferlach T, Duyster J, von Bubnoff N. Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo. Leukemia. 2020 Nov 4. doi: 10.1038/s41375-020-01077-1. Epub ahead of print. PMID: 33149267

Rinke J, Hochhaus A, Ernst T: CML - Not only BCR-ABL1 matters. Best Pract Res Clin Haematol. 2020 Sep;33(3):101194. doi: 10.1016/j.beha.2020.101194. Epub 2020 Jun 7. PMID: 33038988

Miller P, Sperling AS, Gibson CJ, Viswanathan K, Castellano CA, McConkey ME, Ceremsak JJ, Taylor MS, Birndt S, Perner F, Arnason JE, Agrawal M, Schram A, Nikiforow S, Pihan G, Hasserjian RP, Aster JC, La Rosée P, Morgan EA, Berliner N, Ebert BL: Contribution of Clonal Hematopoiesis to Adult-Onset Hemophagocytic Lymphohistiocytosis. Blood. 2020 Sep 22:blood.2020008206. doi: 10.1182/blood.2020008206. Epub ahead of print. PMID: 32961550

Ernst P, Press AT, Fischer M, Günther V, Gräfe C, Clement JH, Ernst T, Schubert US, Wotschadlo J, Lehmann M, Enzensperger C, Bauer M, Hochhaus A:Polymethine Dye-Functionalized Nanoparticles for Targeting CML Stem Cells. Molecular Therapy – Oncolytics, Volume 18, 25 September 2020, Pages 372-381. https://doi.org/10.1016/j.omto.2020.07.007

Eisfeld H, Kircher S, Rosenwald A, Anagnostopoulos I, Werner M, Gaßler N, Wolf G, Lehmkuhl L, Teichgräber U, Gühne F, Darr A, Freesmeyer M, Weschenfelder W, Hofmann G, Dalkilic R, Kalff R, Hochhaus A, Schrenk KG: Revealing the true face behind the mask of ALK-positive anaplastic large cell lymphoma (ALCL) [published online ahead of print, 2020 Sep 8]. Ann Hematol. 2020;10.1007/s00277-020-04247-4. doi:10.1007/s00277-020-04247-4 PMID: 32895754

La Rosée F, La Rosée P: Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies. [published online ahead of print, 2020 Aug 20]. Acta Haematol. 2020;1-3. doi:10.1159/000510770. PMID: 32818929

Wörmann B, Rüthrich M, Einsele H, Tamm I, de Wit M, Trümper L, von Lilienfel-Toal M: COVID-19 un Onkologie. Anpassungsfähiges System. Perspektiven der Onkologie 2/2020 I Deutsches Ärzteblatt. DOI: 10.3238/ PersOnko.20200817.07

Rachow T, Lamik T, Kalkreuth J, Kurze S, Wagner K , Stier P , Hammersen F, Rüthrich M, Winkelmann N, Klink A, Hilgendorf I, Hermann B , Lang S, Hochhaus A, von Lilienfeld-Toal M: Detection of community-acquired respiratory viruses in allogeneic stem-cell transplant recipients and controls-A prospective cohort study [published online ahead of print, 2020 Jul 13]. Transpl Infect Dis. 2020;e13415. doi:10.1111/tid.13415. PMID: 32779843

Roth I, Dubois C, Schmidt T, Hübner J. Attitude of cancer patients from online self-help groups towards physical activity. J Cancer Res Clin Oncol. 2020;146(6):1583-1590. doi:10.1007/s00432-020-03190-1, PMID: 32219516

Büntzel J, Klein M, Keinki C, Walter S, Büntzel J, Hübner J. Oncology services in corona times: a flash interview among German cancer patients and their physicians [published online ahead of print, 2020 May 15]. J Cancer Res Clin Oncol. 2020;146(10):2713-2715. doi:10.1007/s00432-020-03249-z. PMID: 32415341

Kutschan S, Freuding M, Keinki C, Huebner J. Recommendations on complementary and alternative medicine within S3 guidelines in oncology: systematic quality assessment of underlying methodology. J Cancer Res Clin Oncol. 2020;146(9):2419-2425. doi:10.1007/s00432-020-03238-2. PMID: 32394053

Rosenfeldt S, Mickoleit F, Jörke C, Clement JC, Markert S, Jérôme V, Schwarzinger S, Freitag R, Schüler D, Uebe R, Schenk AS: Towards standardized purification of bacterial magnetic nanoparticles for future in vivo applications [published online ahead of print, 2020 Jul 25]. Acta Biomater. 2020;S1742-7061(20)30428-1. doi:10.1016/j.actbio.2020.07.042. PMID: 32721577

Wolff D, Herzberg PY, Herrmann A, Pavletic SZ, Heussner P, Mumm F, Höfer C, Hilgendorf I, Hemmati PG, Holler E, Greinix H, Mitchell SA: Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health [published online ahead of print, 2020 Jul 31]. Bone Marrow Transplant. 2020;10.1038/s41409-020-01017-8. doi:10.1038/s41409-020-01017-8 Copy. PMID: 32737446

Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Sebastien Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Burchert A, Brümmendorf TH, Hasford J, Hochhaus A, Saußele S, Baccarani M, SAKK and the German CML Study Group: High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020;34(8):2074-2086. doi:10.1038/s41375-020-0826-9. PMID: 32382082

Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, Guilhot F, Heibl S, Hehlmann R, Faber E, Turkina A, Ossenkoppele G, Höglund M, Zaritskey A, Griskevicius L, Olsson-Strömberg U, Everaus H, Koskenvesa P, Labar B, Sacha T, Zackova D, Cervantes F, Colita A, Zupan I, Bogdanovic A, Castagnetti F, Guilhot J, Hasford J, Hochhaus A, Hoffmann VS: The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34(8):2138-2149. doi:10.1038/s41375-020-0931-9. PMID: 32601376

Kaiser A, Schmidt M, Huber O, Frietsch J , Scholl S, Heidel F, Hochhaus A, Müller J, Ernst T: SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders. Leukemia. 2020;34(8):2206-2216. doi:10.1038/s41375-020-0803-3. PMID: 32214204

Rinke J, Chase A, Cross NCP, Hochhaus A, Ernst T: EZH2 in Myeloid Malignancies. Cells 9, no. 7: 1639

Schiffl H, Al-Nemnem E, Lang SM. Proton-pump inhibitors and chronic kidney disease: Hidden consequences of an inappropriate drug use?. Saudi J Kidney Dis Transpl. 2020;31(2):312-319. doi:10.4103/1319-2442.284005. PMID: 32394903

Lang SM, Rachow T: Molekulare therapeutische Stratifizierung des nichtkleinzelligen Lungenkarzinoms. Onkologe, https://doi.org/10.1007/s00761-020-00787-6. © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2020

Lang, S.M., Al-Nemnem, E. and Schiffl, H. (2020) Anti-Tuberculosis Drug Induced Liver Injury and Ursodeoxycholic Acid. Journal of Tuberculosis Research, 8, 66-72. https://doi.org/10.4236/jtr.2020.82007

Lang SM: Pneumonitis als gravierende Nebenwirkung bei Asthmapatienten unter Immuntherapie. Kompass Pneumol https://doi.org/10.1159/000509167

Heidel F, Hochhaus A: Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation. Leukemia . 2020;34(7):1723-1725. doi:10.1038/s41375-020-0898-6. PMID: 32528040

Butt E, Stempfle  K, Lister L , Wolf  F , Kraft M, Herrmann AB, Viciano CP, Weber C, Hochhaus A, Ernst T, Hoffmann C, Zernecke A, Frietsch JJ: Phosphorylation-Dependent Differences in CXCR4-LASP1-AKT1 Interaction Between Breast Cancer and Chronic Myeloid Leukemia. Cells. 2020 Feb 14;9(2):444. doi: 10.3390/cells9020444. PMID: 32075106

Frietsch JJ, Hunstig F, Wittke C, Junghanss C, Franiel T, Scholl S, Hochhaus A, Hilgendorf I: Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity. Bone Marrow Transplant (2020). https://doi.org/10.1038/s41409-020-0984-4

Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S,  Guilhot F,  Heibl S, Hehlmann R, Faber E,  Turkina A, Ossenkoppele G, Höglund M, Zaritskey A, Griskevicius L, Olsson-Strömberg U, Everaus H, Koskenvesa P, Labar B, Sacha T, Zackova D, Cervantes F, Colita A, Zupan I, Bogdanovic A,  Castagnetti F, Guilhot J, Hasford J, Hochhaus A, Hoffmann VS:The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia (2020). https://doi.org/10.1038/s41375-020-0931-9

Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brümmendorf TH, Smith BD, Ernst T, Giraldo-Castellano P, Olsson-Strömberg U, Saussele S, Bardy-Bouxin N, Viqueira A, Leip E, Russell-Smith TA, Leone J, Rosti G, Watts J, Giles FJ, on behalf of the BYOND Study Investigators: Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia (2020). https://doi.org/10.1038/s41375-020-0915-9

La Rosée, F., Bremer, H.C., Gehrke, I. et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia (2020). https://doi.org/10.1038/s41375-020-0891-0

Ortmann, J. Torode, W. Schmiegel, C. Thomssen, M. Hakama, P. Basu, U. Ringborg, U. Helbig, For the participants of the ERTM: Knowledge transfer as a tool towards improvement of cancer care in low‑ and middle‑income countries. 6th European Roundtable Meeting (ERTM), June 14th, 2019, Berlin, Germany. Journal of Cancer Research and Clinical Oncology (2020) 146:1813–1818 https://doi.org/10.1007/s00432-020-03209-7 REVIEW – CLINICAL ONCOLOGY. Received: 31 March 2020 / Accepted: 2 April 2020 / Published online: 8 April 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020 PMID: 32270287

Joseph Tintelnot, Eray Goekkurt, Mascha Binder, Peter Thuss-Patience, Sylvie Lorenzen, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Thomas Ettrich, Udo Lindig, Lutz Jacobasch, Daniel Pink, Salah-Eddin Al-Batran, Axel Hinke, Susanna Hegewisch-Becker, Sven Nilsson, Carsten Bokemeyer, Alexander Stein: Ipilimumab or FOLFOX With Nivolumab and Trastuzumab in Previously Untreated HER2-positive Locally Advanced or Metastatic EsophagoGastric Adenocarcinoma - The Randomized Phase 2 INTEGA Trial (AIO STO 0217). BMC Cancer . 2020 Jun 1;20(1):503. doi: 10.1186/s12885-020-06958-3. PMID: 32487035

Christoph Röllig, Michael Kramer, Christoph Schliemann, Jan-Henrik Mikesch, Björn Steffen, Alwin Krämer, Richard Noppeney, Kerstin Schäfer-Eckart, Stefan Krause, Mathias Hänel, Regina Herbst, Volker Kunzmann, Hermann Einsele, Edgar Jost, Tim H. Brümmendorf, Sebastian Scholl, Andreas Hochhaus, Andreas Neubauer, Kristina Sohlbach, Lars Fransecky, Martin Kaufmann, Dirk Niemann, Markus Schaich, Norbert Frickhofen, Alexander Kiani, Frank Heits, Ulrich Krümpelmann, Ulrich Kaiser, Johannes Kullmer, Maxi Wass, Friedrich Stölzel, Malte von Bonin, Moritz Middeke, Christian Thiede, Johannes Schetelig, Wolfgang E Berdel, Gerhard Ehninger, Claudia D Baldus, Carsten Müller-Tidow, Uwe Platzbecker2, Hubert Serve, Martin Bornhäuser: Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood (2020) 136 (7): 823–830.https://doi.org/10.1182/blood.2019004583

Silvio Dutz, Norbert Buske, Joachim Landers , Christine Gräfe , Heiko Wende , Joachim H Clement: Biocompatible Magnetic Fluids of Co-Doped Iron Oxide Nanoparticles With Tunable Magnetic Properties. Nanomaterials (Basel), 2020 May 27;10(6):E1019. doi: 10.3390/nano10061019, PMID:  32471031

Sebastian Stasik , Jan M Middeke , Michael Kramer , Christoph Röllig , Alwin Krämer , Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H Brümmendorf, Ralph Naumann, Björn Steffen, Volker Kunzmann, Hermann Einsele, Markus Schaich, Andreas Burchert, Andreas Neubauer, Kerstin Schäfer-Eckart, Christoph Schliemann, Stefan Krause, Regina Herbst, Mathias Hänel, Norbert Frickhofen, Richard Noppeney, Ulrich Kaiser, Claudia D Baldus, Martin Kaufmann, Zdenek Rácil, Uwe Platzbecker , Wolfgang E Berdel , Jiri Mayer , Hubert Serve , Carsten Müller-Tidow , Gerhard Ehninger , Martin Bornhäuser , Johannes Schetelig , Christian Thiede , Study Alliance Leukemia (SAL): Haematologica. 2020 May;105(5):e228-e231. doi: 10.3324/haematol.2019.222323.  Epub 2019 Aug 14. EZH2 Mutations and Impact on Clinical Outcome: An Analysis in 1,604 Patients With Newly Diagnosed Acute Myeloid Leukemia, PMID: 31413097

Katerina Machova Polakova , Hana Zizkova , Jan Zuna , Eliska Motlova , Lenka Hovorkova , Andrea Gottschalk, Ingmar Glauche , Jitka Koblihova, Pavla Pecherkova , Hana Klamova , Marketa Stastna Markova , Dana Srbova , Adela Benesova , Vaclava Polivkova , Tomas Jurcek , Daniela Zackova , Jiri Mayer , Thomas Ernst , Francois X Mahon , Susanne Saussele , Ingo Roeder , Nicholas C P Cross , Andreas Hochhaus: Analysis of Chronic Myeloid Leukaemia During Deep Molecular Response by Genomic PCR: A Traffic Light Stratification Model With Impact on Treatment-Free Remission. Leukemia. . 2020 May 29. doi: 10.1038/s41375-020-0882-1.  Online ahead of print. PMID: 32472084

Midic D, Rinke J, Perner F, Müller V, Hinze A, Pester F, Landschulze J, Ernst J, Gruhn B, Matziolis G, Heidel F , Hochhaus A, Ernst T: Prevalence and Dynamics of Clonal Hematopoiesis Caused by Leukemia-Associated Mutations in Elderly Individuals Without Hematologic Disorders. Leukemia. 2020 May 26. doi: 10.1038/s41375-020-0869-y. Online ahead of print. PMID: 32457355

Roth I, Dubois C, Schmidt T, Jutta Hübner J: Attitude of Cancer Patients From Online Self-Help Groups Towards Physical Activity. J Cancer Res Clin Oncol . 2020 Jun;146(6):1583-1590. doi: 10.1007/s00432-020-03190-1.  Epub 2020 Mar 26. PMID: 32219516

Peter G. Miller, Abhishek Niroula, John J. Ceremsak, Christopher J. Gibson, Martin S. Taylor, Sebastian Birndt, Florian Perner, Jon Arnason, Adam S. Sperling, Mridul Agrawal, Alison M. Schram, Sarah Nikiforow, German Pihan, Robert P. Hasserjian, Jon C. Aster, Paul La Rosée,Elizabeth A. Morgan, Nancy Berliner, and Benjamin L. Ebert: Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. Blood Adv . 2020 Mar 10;4(5):925-929. doi: 10.1182/bloodadvances.2019001272. PMID: 32150605

Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, Hochhaus A, Lüftner D, Müller OJ, Neudorf U, Pfister R, von Haehling S, Lehmann LH, Bauersachs J; Committee for Clinical Cardiovascular Medicine of the German Cardiac Society: Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol. 2020 May 13. doi: 10.1007/s00392-020-01636-7. [Epub ahead of print] PMID: 32405737

Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, Hochhaus A, Lüftner D, Müller OJ, Neudorf U, Pfister R, von Haehling S, Lehmann LH, Bauersachs J; für die Kommission für Klinische KardiovaskuläreMedizin der DGK: Onkologische Kardiologie Konsensuspapier der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung, der Deutschen Gesellschaft für Pädiatrische Kardiologie und Angeborene Herzfehler und der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie. Kardiologe https://doi.org/10.1007/s12181-020-00395-z

von Lilienfeld-Toal M: Community-Acquired Respiratory Viruses in Oncology: Lessons to Be Learnt from the SARS-CoV-2 Pandemic. Oncol Res Treat. 2020 May 14:1-2. doi: 10.1159/000508452. [Epub ahead of print] PMID: 32408304

Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, Butler MO, Delord JP, Gelderblom H, Ascierto PA, Fasolo A, Führer D, Hütter-Krönke ML, Forde PM, Wrona A, Santoro A, Sadow PM, Szpakowski S, Wu H, Bostel G, Faris J, Cameron S, Varga A, Taylor M: PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020 May 4:JCO1902727. doi: 10.1200/JCO.19.02727. [Epub ahead of print] PMID: 32364844

Hehlmann R, Voskanyan A, Lauseker M, Markus Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb H, Neubauer A, Hossfeld D, Nerl C, Gratwohl A, Baerlocher G, Burchert A, Brümmendorf T, Hasford J, Hochhaus A, Saußele S, Baccarani M for the SAKK and the German CML Study Group: High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia, https://doi.org/10.1038/s41375-020-0826-9. Received: 27 February 2020 / Revised: 2 March 2020 / Accepted: 30 March 2020, © The Author(s) 2020. This article is published with open access

Hochhaus A, Breccia M, Saglio G, García-Gutiérrez V, Réa D, Janssen J, Apperley J: Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia, https://doi.org/10.1038/s41375-020-0842-9, Received: 9 April 2020 / Revised: 16 April 2020 / Accepted: 16 April 2020

von Lilienfeld-Toal M, Vehreschild JJ, Cornely O, Pagano L, Compagno F; EHA Infectious Disease Scientific Working Group, Hirsch HH: Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases. Leukemia. 2020 May 1. doi: 10.1038/s41375-020-0832-y. [Epub ahead of print] PMID: 32358568

Hans-Jürgen Laws, Ulrich Baumann, Christian Bogdan, Gerd Burchard, Maximilian Christopeit, Jane Hecht, Ulrich Heininger, Inken Hilgendorf, Winfried Kern, Kerstin Kling, Guido Kobbe, Wiebe Külper,·Thomas Lehrnbecher, Roland Meisel, Arne Simon, Andrew Ullmann: Maike de Wit16, 17 · Fred Zepp4, 18Impfen bei Immundefizienz. Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsbl 2020 · 63:588–644; https:// doi.org/ 10.1007/ s00103- 020- 03123-w; © Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2020

Schwaab J, Naumann N, Luebke J, Jawhar M, Somervaille TCP, Williams MS, Frewin R, Jost PJ, Lichtenegger FS, La Rosée P, Storch N, Haferlach T, Horny HP, Fabarius A, Haferlach C, Burchert A, Hofmann WK, Cross NCP, Hochhaus A, Reiter A, Metzgeroth G: Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Am J Hematol. 2020 Apr 12. doi: 10.1002/ajh.25825. [Epub ahead of print] PMID: 32279331

Chase A, Score J, Lin F, Bryant C, Waghorn K, Yapp S, Carreno-Tarragona G, Aranaz P, Villasante A, Ernst T, Cross NCP3: Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia. 2020 Apr 22. doi: 10.1038/s41375-020-0816-y. [Epub ahead of print] PMID: 32322039

von Lilienfeld-Toal M, Rüthrich MM, Mathies V, Wingen-Heimann S, Vehreschild JJ, Wörmann B: SARS-CoV-2: Vorgehen in der Krebstherapie. Dtsch Arztebl 2020; 117(16): A-820 / B-694

Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, Hochhaus A, Kim DW, Radich J, Savona M, Martin-Regueira P, Sy O, Gurnani R, Saglio G: Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia. 2020 Apr 7. doi: 10.1038/s41375-020-0805-1. [Epub ahead of print] PMID: 32265500

Gale, R.P., Hehlmann, R. & Hochhaus, A. Clara Bloomfield MD: Queen of AML. Dare to cross her at your risk (May 15, 1942 to March 1, 2020). Bone Marrow Transplant (2020). https://doi.org/10.1038/s41409-020-0881-x This article is co-published in the journals Bone Marrow Transplantation and Leukemia. [https://doi.org/10.1038/s41375-020-0807-z. of LEU].

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R: European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Mar 3. doi: 10.1038/s41375-020-0776-2. [Epub ahead of print] PMID: 32127639

Birndt S, Schenk T,  Heinevetter B, Brunkhorst F, Maschmeyer G, Rothmann F, Thomas Weber T, Müller M, Panse J, Penack O, Schroers R, Braess J, Frickhofen N, Ehl S, Janka G, Lehmberg K, Pletz M, Hochhaus A, Ernst T,and Paul La Rosée P: Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry. J Cancer Res Clin Oncol. 2020 Apr;146(4):1065-1077. doi: 10.1007/s00432-020-03139-4. Epub 2020 Feb 20. PMID: 32076823

Kaiser A, Schmidt M, Huber O, Frietsch J, Scholl S, Heidel F, Hochhaus A, Müller J, Ernst T: 3ARTICLEStem cell biologySIRT7: an influence factor in healthy aging and the developmentof age-dependent myeloid stem-cell disorders. Leukemia, https://doi.org/10.1038/s41375-020-0803-3

Ernst P, Engmann B, Frietsch JJ, Schnetzke U, Scholl S, Theis B, Kreipe HH, Ernst T, Glaser A, Haferlach T, Koch T, Hochhaus A, Hilgendorf I: A 19-year-old patient with atypical chronic myeloid leukemia. Ann Hematol. 2020 Mar 19. doi: 10.1007/s00277-020-03992-w. [Epub ahead of print] PMID: 32193626

Eisfeld H, Bauer F, Dubois C, Schmidt T, Kastrati K, Hochhaus A, Hübner J: Importance of and Satisfaction with Information about Their Disease in Cancer Patients. J Cancer Educ. 2020 Apr;35(2):403-411. doi: 10.1007/s13187-019-1480-7. PMID: 30684231

Miller PG, Niroula A, Ceremsak JJ, Gibson CJ, Taylor MS, Birndt S, Perner F, Arnason J, Sperling AS, Agrawal M, Schram AM, Nikiforow S, Pihan G, Hasserjian RP, Aster JC, La Rosée P, Morgan EA, Berliner N, Ebert BL: Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. Blood Adv. 2020 Mar 10;4(5):925-929. doi: 10.1182/bloodadvances.2019001272. PMID: 32150605  

Hoffmann K, Cazemier K, Baldow C, Schuster S, Kheifetz Y, Schirm S, Horn M, Ernst T, Volgmann C, Thiede C, Hochhaus A, Bornhäuser M, Suttorp M, Scholz M, Glauche I, Loeffler M, Roeder I: Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology. BMC Med Inform Decis Mak. 2020 Feb 10;20(1):28. doi: 10.1186/s12911-020-1039-x. PMID: 32041606

Metzgeroth G, Schwaab J, Naumann N, Jawhar M, Haferlach T, Fabarius A, Hochhaus A, Hofmann WK, Cross NCP, Reiter A: Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation. Blood Adv. 2020 Feb 11;4(3):440-443. doi: 10.1182/bloodadvances.2019001111. PMID: 31995156

Salchow J, Mann J, Koch B, von Grundherr J, Jensen W, Elmers S, Straub LA, Vettorazzi E, Escherich G, Rutkowski S, Dwinger S, Bergelt C, Sokalska-Duhme M, Bielack S, Calaminus G, Baust K, Classen CF, Rössig C, Faber J, Faller H, Hilgendorf I, Gebauer J, Langer T, Metzler M, Schuster S, Niemeyer C, Puzik A, Reinhardt D, Dirksen U, Sander A, Köhler M, Habermann JK, Bokemeyer C, Stein A: Comprehensive assessments and related interventions to enhance the long-term outcomes of child, adolescent and young adult cancer survivors - presentation of the CARE for CAYA-Program study protocol and associated literature review. BMC Cancer. 2020 Jan 6;20(1):16. doi: 10.1186/s12885-019-6492-5. PMID: 31906955

Beelen DW, Trenschel R, Stelljes M, Groth C , Masszi T, Reményi P , Wagner-Drouet E , Hauptrock B, Dreger P, Luft T, Bethge W, Vogel W, Ciceri F, Jacopo Peccatori J , Stölzel F, Schetelig J, Junghanß C , Grosse-Thie C, Michallet M, Labussiere-Wallet H, Schaefer-Eckart K, Dressler S, Grigoleit GU, Mielke S, Scheid C, Holtick U, Patriarca F, Medeot M, Rambaldi A, Micò MC, Niederwieser D, Franke G, Hilgendorf I, Winkelmann N, Russo D, Socié G, de Latour RP, Holler E, Wolff D, Glass B, Casper J, Wulf G, Menzel H, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, Grass S, Iori AP , Finke J, Benedetti F, Pichlmeier U, Hemmelmann C, Tribanek M, Klein A, Mylius HA, Baumgart J, Dzierzak-Mietla M, Markiewicz M: Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7(1):e28-e39. doi:10.1016/S2352-3026(19)30157-7. PMID: 31606445